AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8279841
Drug: CP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP therapy (cyclophosphamide 600 mg/m2 + CDDP 75 mg/m2)
Trial: 16806
Drug: Cimetidine, 400
RxNorm normalized name: Cimetidine, 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 400 mg
Trial: 2979681
Drug: Aspirin (1300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1300 mg, 36 mmol)
Trial: 2979681
Drug: Control for
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control for aspirin (36 mmol HCl)
Trial: 22639135
Drug: Levobupivacaine labor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine labor epidural (bolus concentration 0.25 % or less; infusion concentration 0.125 % or less)
Trial: 22639135
Drug: Combined spinal‐epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined spinal‐epidural procedure (morphine 0.20 mg, fentanyl 25 µg and hyperbaric bupivacaine 2.5 mg)
Trial: 17707079
Drug: Sequential intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential intervention (PA at baseline and FI at 3 months)
Trial: 17707079
Drug: Sequential intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential intervention (FI at baseline and PA at 3 months)
Trial: 16883901
Drug: Chemotherapy (Western
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Western group)
Trial: 16883901
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of TCM and chemotherapy (Integrative group)
Trial: 12823702
Drug: 15% EDTAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% EDTAC solution
Trial: 10608756
Drug: Antenatal zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antenatal zidovudine treatment for 2 weeks
Trial: 10608756
Drug: Antenatal zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antenatal zidovudine treatment
Trial: 1514169
Drug: Heparin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (500 U heparin/h for 30 h)
Trial: 6370007
Drug: Antacid (usually
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid (usually Mylanta II)
Trial: 22671310
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser therapy
Trial: 31246661
Drug: Promestriene (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promestriene (10 mg intravaginal cream 3 times a week)
Trial: 29467849
Drug: IMRT combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT combined with chemotherapy
Trial: 25428394
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy and chemotherapy
Trial: 17481836
Drug: Sweat patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweat patches worn for 7 days after cessation of cannabis use
Trial: 17481836
Drug: Oral doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses of up to 14.8 mg THC/day for five consecutive days
Trial: 11938417
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant human erythropoietin 200 U/kg/day and iron 1mg/kg/day
Trial: 10484096
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (trained twice)
Trial: 2198378
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg xipamide/day
Trial: 2198378
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg spironolactone/day combined with 40 mg of furosemide every other day
Trial: 602716
Drug: Dexamethasone (Decadron,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (Decadron, 2 mg 3 times a day for 4 days)
Trial: 602716
Drug: Control (64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (64 patients, no treatment mentioned)
Trial: 30041167
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (ICBT) for 12 weeks
Trial: 26044872
Drug: Budesonide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (2 mg/day)
Trial: 18765950
Drug: Topical cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporine A 0.05% (tCsA) eye drops
Trial: 18765950
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (tCsA) and Control group
Trial: 16846555
Drug: Racemic albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic albuterol (180 microg)
Trial: 16846555
Drug: Levalbuterol and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levalbuterol and racemic albuterol
Trial: 14984495
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection (UKALL X protocol, n = 40)
Trial: 14984495
Drug: Infusion (UKALL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion (UKALL XI protocol, n = 71)
Trial: 11713062
Drug: Initial medical
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial medical therapy
Trial: 30428290
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg per day for 14 days, then 20 mg per day for 14 days)
Trial: 25760973
Drug: Bevacizumab added
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab added to chemotherapy (cisplatin and paclitaxel)
Trial: 16524859
Drug: Orlistat (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat (120 mg orally 3 times a day)
Trial: 10606839
Drug: Cimetidine 100
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 100 mg twice daily
Trial: 9105568
Drug: E2/NETA (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/NETA (continuous oral 17 beta‐estradiol 2 mg/day combined with norethisterone acetate 1 mg/day)
Trial: 9105568
Drug: E2/MPA (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/MPA (transdermal 17 beta‐estradiol 50 micrograms/day combined with cyclic medroxyprogesterone acetate 10 mg/day)
Trial: 8622034
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy (no BRT)
Trial: 3084269
Drug: 20% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% glucose infusion for 2 hours
Trial: 3084269
Drug: 8% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% amino acid infusion for 2 hours
Trial: 11844036
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline solution (control)
Trial: 31977921
Drug: Infrared sauna
RxNorm normalized name: Sana leaf
DrugBank: Senna leaf (DB15889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrared sauna treatment
Trial: 27067394
Drug: Sonidegib 200
RxNorm normalized name: sonidegib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonidegib 200 mg
Trial: 27262419
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg IV‐TXA before skin incision (group A)
Trial: 27262419
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg IV‐TXA 3 hours later (group B)
Trial: 27262419
Drug: Two boluses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two boluses of 10 mg/kg IV‐TXA at 3 and 6 hours later (group C)
Trial: 25722196
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg q24h for 9 months)
Trial: 25722196
Drug: Isoniazid (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid (300 mg q24h for 9 months)
Trial: 23052809
Drug: Intravenous cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefazolin 1 g
Trial: 20642418
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 3-monthly spirometry with regular medical review
Trial: 18821166
Drug: Activating both
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activating both the solutions and blocking words for a particular fragment at study
Trial: 12061361
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of indomethacin (n = 14)
Trial: 12061361
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of indomethacin (n = 18)
Trial: 2110199
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg per injection of IFN, subcutaneous injections three times weekly
Trial: 2110199
Drug: 0.02 mg
RxNorm normalized name: escin 0.02 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02 mg of IFN, subcutaneous injections three times weekly
Trial: 2110199
Drug: Placebo, subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, subcutaneous injections three times weekly
Trial: 6110582
Drug: Standard-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose oral contraceptives (50 microgram of estrogen)
Trial: 6110582
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptives (30 microgram of estrogen)
Trial: 6110582
Drug: Both standard-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both standard-dose and low-dose oral contraceptives
Trial: 2678880
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptives
Trial: 31904309
Drug: 250 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL distilled water with 10-minute rest in a supine position
Trial: 31904309
Drug: 250 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL distilled water with 30-minute rest in a supine position
Trial: 25733482
Drug: Lipid-based nutrient
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-based nutrient supplement (LNS) fortified with multiple micronutrients (MMNs)
Trial: 25733482
Drug: MMN supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMN supplement
Trial: 24657484
Drug: TG4040 followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TG4040 followed by PEG‐IFNα/RBV for 48 weeks with 6 injections of TG4040 (group C)
Trial: 24657484
Drug: PEG‐IFNα/RBV for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFNα/RBV for 4 weeks followed by PEG‐IFNα/RBV for 44 weeks with 6 injections of TG4040 (group B)
Trial: 8959472
Drug: Lesopitron 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesopitron 20, 25, 30, 40, 45, 50, and 60 mg two times a day
Trial: 8959472
Drug: Lesopitron 60
RxNorm normalized name: Lesopitron
DrugBank: Lesopitron (DB04970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesopitron 60 mg two times a day
Trial: 8959472
Drug: Lesopitron (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesopitron (various doses)
Trial: 1304766
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IGIV) 500 mg/kg
Trial: 12357165
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine infusion
Trial: 18848786
Drug: Estramustine (E)
DrugBank: Estramustine phosphate (DB14674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estramustine (E) 840 mg/day divided into three daily administrations on days 1-5 plus DOC 70 mg/m² on day 2
Trial: 15800138
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no anti-Alzheimer drugs)
Trial: 27537360
Drug: Blue LED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue LED light treatment (emission maximum: 453 nm), 3 times per week for 4 weeks
Trial: 25047311
Drug: 1% feracrylum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% feracrylum citrate solution
Trial: 17942609
Drug: Peptide-DC vaccine
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide-DC vaccine (3 million versus 10 million) administered intravenously or subcutaneously
Trial: 17942609
Drug: Peptide-DC vaccine
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide-DC vaccine
Trial: 15696987
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% clindamycin solution
Trial: 8913976
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of PGE2 gel
Trial: 8913976
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg of PGE2 gel
Trial: 1859518
Drug: CM 40907
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM 40907 (1200 mg)
Trial: 1859518
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA, 1000 mg)
Trial: 1859518
Drug: CM 40907
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM 40907 (600 mg and 900 mg)
Trial: 6355052
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir treatment (200 mg, 5 times daily) for first episode HSV
Trial: 6355052
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir treatment for recurrent HSV
Trial: 24332218
Drug: BI 671800
RxNorm normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 671800 (200 mg twice daily)
Trial: 24332218
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray (200 μg once daily)
Trial: 24332218
Drug: BI 671800
RxNorm normalized name: BI-671800
DrugBank: BI-671800 (DB12524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 671800 (all doses)
Trial: 15711245
Drug: Chronic urinary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic urinary retention with large residual urine volumes (greater than 300 ml)
Trial: 12193309
Drug: Single enema
RxNorm normalized name: docusate
DrugBank: Docusate (DB11089)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single enema (400 mg of PTU in 90 mL of sterile water)
Trial: 12193309
Drug: Two suppositories
RxNorm normalized name: potassium bitartrate / sodium bicarbonate Rectal Suppository [Ceo-Two]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two suppositories of polyethylene glycol base (200 mg of PTU in each)
Trial: 12193309
Drug: Both forms
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both forms of PTU (enema and suppository)
Trial: 16879331
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser preparation
Trial: 16942429
Drug: Conventional mechanical
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional mechanical preparation
Trial: 27431570
Drug: Kang'ai Xiaoshui
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kang'ai Xiaoshui ointment
Trial: 23870239
Drug: Lidocaine pump
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine pump spray
Trial: 18666504
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L-Pop
Trial: 19132414
Drug: Two experimental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two experimental formulations
Trial: 11255136
Drug: Potassium phosphate
RxNorm normalized name: Potassium phosphate
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium phosphate supplementation (4,000 mg x day(-1) for 2 days)
Trial: 9875688
Drug: Grape procyanidin
RxNorm normalized name: procyanidin A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape procyanidin extracts (Leucoselect-phytosome) 300 mg, taken as two capsules daily for 5 days.
Trial: 9875688
Drug: Placebo, taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken as two capsules daily for 5 days.
Trial: 2603606
Drug: Other forms
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other forms of treatment (Group B)
Trial: 31128926
Drug: Enhanced upper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced upper limb therapy (EULT)
Trial: 18162423
Drug: Glutamate or
RxNorm normalized name: glutamate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamate or Capsaicin injection
Trial: 10555884
Drug: Alendronate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (40 mg oral AL/day)
Trial: 1974748
Drug: Beta‐adrenoceptor blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta‐adrenoceptor blocking agents (treated group, n = 39)
Trial: 1974748
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 22, no preoperative beta-blocker therapy)
Trial: 15998890
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg every other day)
Trial: 11860644
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray administration
Trial: 11860644
Drug: Nasal drop
RxNorm normalized name: Nasal Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal drop administration
Trial: 10442381
Drug: UFT (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (150 mg/m2/day) plus oral calcium folinate (90 mg/day) plus radiotherapy (45 Gy total)
Trial: 7844596
Drug: Chemotherapy (CHEMO)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CHEMO)
Trial: 2895592
Drug: Midazolam 15
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 15 mg and Temazepam 20 mg
Trial: 23886213
Drug: GEMOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEMOX regimen (gemcitabine at 1000 mg/m² by fixed-dose rate infusion at 10 mg/m²/min on days 1 and 8, and oxaliplatin at 100 mg/m² on day 1, repeated every 3 weeks)
Trial: 23886213
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (gemcitabine at 1000 mg/m² by intravenous infusion within 30 min on days 1 and oxaliplatin at 100 mg/m² on day 1, repeated every 3 weeks)
Trial: 20541220
Drug: Olanzapine augmentation
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine augmentation (olanzapine + divalproex)
Trial: 3394908
Drug: Diazepam in
RxNorm normalized name: diazePAM Intensol
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam in lipid formulation
Trial: 30740748
Drug: Gabapentin (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (maximum daily dose of 900 mg)
Trial: 30740748
Drug: Baclofen (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (maximum daily dose of 60 mg)
Trial: 29964036
Drug: Genotypic resistance-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotypic resistance-guided therapy for 14 days (n=21 in trial 1, n=205 in trial 2)
Trial: 29964036
Drug: Empirical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical therapy for 14 days (n=20 in trial 1, n=205 in trial 2)
Trial: 29964036
Drug: Doxycycline sequential
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline sequential therapy (part of trial 1)
Trial: 22915637
Drug: DAS 100
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAS 100 mg/day
Trial: 22915637
Drug: IM 400
RxNorm normalized name: Bactrim 400mg-80mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM 400 mg/day
Trial: 11581440
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (IR MPH) 3 times a day (tid)
Trial: 2646838
Drug: Premedication with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication with 10 mg isosorbide dinitrate sublingually
Trial: 28281196
Drug: Inhalation via
RxNorm normalized name: propyliodone 60 % INHALATION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation via I‐neb®